This page shows what was measured, who it was measured in, and what that does not settle.
What Eplerenone does in the body
From the FDA-approved label: Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS).
Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. , heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms.
Why people take it. Hypertension
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 6995V82D0B · read 2026-08-29
Its recorded molecular formula is C24H30O6, weighing 414.50.
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The recorded use, written for a reader without medical training. Not signed off.
No statement of the main limit is recorded.
The four opening statements run to 80 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 39 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Blood sugar
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
△Only a number moved5 registered test measure.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Healthy ageing
…Waiting for a reviewer3 registered study measure of this kind. No reviewed result yet.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
mortality; all cause hospitalization or all cause mortality; all cause mortality
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
△ Only a number moved
5 registered test measure.
— Not recorded
Harms were not a registered measure for this goal.
… Waiting for a reviewer
Who was studied is listed further down the page.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Frequency of PA testing orders by provider
✗ The study did not show it
Who was studied
NCT05925569
How many people
12501
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Mortality
✗ The study did not show it
Who was studied
NCT03984591
How many people
7200
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date
✗ The study did not show it
Who was studied
NCT00232180
How many people
2743
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Patients with uncontrolled BP on ABPM
✗ The study did not show it
Who was studied
NCT06275763
How many people
2500
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Incidence rate for total heart failure (HF) hospitalizations or cardiovascular (CV) death
✗ The study did not show it
Who was studied
NCT02901184
How many people
2000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Composite rate of cardiovascular disease mortality and recurrent heart failure hospitalizations over study duration
✗ The study did not show it
Who was studied
NCT07569640
How many people
1672
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.3 registered measures of this kind. 1 written-up study measured this and did not show a benefit.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.13 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
decrease in supine systolic blood pressure
blood pressure by home measurements
seated trough cuff diastolic blood pressure at week 8
glycated hemoglobin
plasma insulin
insulin secretion
insulin sensitivity
sitting systolic and diastolic blood pressure
insulin sensitivity index
maximum serum concentration
and 3 more.
Meaningful
Things that change how a life goes, not only a number.
mortality
all cause hospitalization or all cause mortality
all cause mortality
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (23)
left ventricular mass
proteinuria
basal metabolic rate
pulse wave velocity
clinically significant effects
cmax
cortisol
adiponectin
nt probnp
ascites
galectin 3
muscle sympathetic nerve activity at rest
disposition index
adverse events as a measure of safety and tolerability
iohexol clearance
area under the curve
half life
elimination rate constant
liver fat content
vascular function
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 3 to 6 hours hours
Read from the label, which states: “12.3 Pharmacokinetics Eplerenone is cleared predominantly by cytochrome P450 (CYP) 3A4 metabolism, with an elimination half-life of 3 to 6 hours.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
INSPRA is an aldosterone antagonist indicated for: • Improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. ( 1.1 ) • The treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of INSPRA for treatment of hypertension have not been established in pediatric patients.”
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
On older people, the label states: “Heart Failure Post-Myocardial Infarction Of the total number of patients in EPHESUS, 3340 (50%) were 65 and over, while 1326 (20%) were 75 and over.”
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary The available data from published case reports on eplerenone use during pregnancy are insufficient to establish a drug-associated risk of major birth defects, miscarriage, adverse maternal or fetal outcomes (see Clinical Considerations ) .”
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There are no human data available on whether eplerenone is present in human milk, or has effects on breastfed infants or on milk production.”
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, tablet, coated, tablet, film coated, given by the oral route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Eplerenone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1369 reaction mentions were counted. One report can name several reactions.
The recorded terms (10)
acute kidney injury — 272 reaction mentions
hypotension — 193 reaction mentions
hyperkalaemia — 162 reaction mentions
cardiac failure — 161 reaction mentions
dyspnoea — 158 reaction mentions
oedema peripheral — 110 reaction mentions
condition aggravated — 92 reaction mentions
drug interaction — 88 reaction mentions
hyponatraemia — 73 reaction mentions
blood creatinine increased — 60 reaction mentions
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
35 products list this as an active ingredient in the United States drug directory. 35 of them contain it and nothing else.
FDA National Drug Code directory · 63190-0800 · read 2026-08-29
They are sold as powder, tablet, tablet, coated and tablet, film coated, taken oral.
FDA National Drug Code directory · 63190-0800 · read 2026-08-29
The regulator's established pharmacologic class for it is aldosterone antagonist [epc] and aldosterone antagonists [moa].
FDA National Drug Code directory · 63190-0800 · read 2026-08-29
13 published labels name it as an active ingredient. 13 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-29
Inspra is oral at 3 DOSAGE FORMS AND STRENGTHS • 25 mg tablets: yellow diamond biconvex film-coated tablets debossed with “VLE” on one side and “NSR” over “25” on the other • 50 mg tablets: yellow diamond biconvex film-coated tablets deb…, recorded as fda label in effect 2025-06-23 in the United States.
US prescribing information · 1a52bedc-8e2c-4116-a296-a87770676b4a · read 2026-08-30
Recorded price in US: 0.30519–0.4659 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 30 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Eplerenone studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Eplerenone are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
13 documents were read for this substance.
RNAWiki source record
13 of them state the same halfLife, and they agree.
RNAWiki source record
13 of them state the same bioavailability, and they agree.
RNAWiki source record
13 of them state the same tMax, and they agree.
RNAWiki source record
13 of them state the same proteinBinding, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
6995V82D0B
RxNorm concept
351256
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
10 approved applications cover products containing this substance. The earliest was NDA021437, approved 20020927 to UPJOHN.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (15)
Q1
What did Eplerenone's largest trial (22213 people) and its longest (16 years) measure?
22213 people in Eplerenone's largest registered study, 16 years in its longest registered window, measuring Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date. ClinicalTrials.gov · 2026-09-01
35 phase4, 22 phase2, 16 phase3, 14 na, 10 phase1, 6 na or unstated, 3 early phase1; NCT00223717; 2017-01; no ageing endpoint recorded. Last human test completed 2025, NCT04519164.
Interpretation These counts include studies where Eplerenone was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase4
35
phase2
22
phase3
16
na
14
phase1
10
na or unstated
6
2 more recorded rows
early phase1
3
Last recorded human testNCT04519164
2025-09-17
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Eplerenone shown lifespan?
Interpretation Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date — the recorded outcome words.
Show the evidence
mouse
mechanism-only
rat
mechanism-only
humanNCT00232180
lifespan; Number of Participants With First Occurrence of Cardiovascular (CV) Mortality or Hospitalization Due to Heart Failure (HF) (Adjudicated): Up to Cut-off Date; 102
recorded 2026-09-01 · last checked 2026-09-04
Q3
18 of Eplerenone's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?
safety (1), futility/efficacy (1), accrual/recruitment (6), funding/business (4) and other (6): Eplerenone's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"Lack of eligible patients"; 18 of 102 registered studies
Show the evidence
Trial
NCT00293150
terminated; "Lack of eligible patients"
NCT00608465
terminated; "Lack of enrollment"
NCT00647192
terminated; "Inclusion rate too low. Recruitment of further study centers too costly."
NCT00649311
terminated; "Poor enrollment; termination not due to safety reasons."
NCT00825188
terminated; "funding to complete was inadequate"
NCT00980031
terminated; "Funding ended prior to study completion"
12 further recorded trials
NCT01100203
terminated; "It was not possible within the time frame to recruit the planned no. of patients."
NCT01275352
withdrawn; "Lack of funding"
NCT01302236
withdrawn; "We could not find patients who agreed to enrolled this clinical study."
NCT01708798
terminated; "Futility"
NCT01794091
withdrawn; "No participants were enrolled in the trial."
NCT01801228
withdrawn; "difficulties to include patients"
NCT01887119
terminated; "Failure to recruit sufficient participants"
NCT01971593
terminated; "Investigator left institution"
NCT02957435
withdrawn; "Study has been cancelled and it has not been initiated."
NCT03418649
withdrawn; "Unable to recruit subjects"
NCT04300881
terminated; "Enrollment"
NCT04746495
withdrawn; "Issues relate to COVID-19 and staffing challenges, as well as very tight finances."
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Eplerenone used Eplerenone 50mg — over how long?
8 recorded entries; human; also "25mg Eplerenone", "Eplerenone 25 mg", "Eplerenone 50 mg"
Show the evidence
human
NCT01822561
Eplerenone 50mg
NCT01990677
25mg Eplerenone
NCT02607657
Eplerenone 25 mg
NCT02607657
Eplerenone 50 mg
NCT02607657
Eplerenone 100 mg
NCT02607657
Eplerenone 50 mg twice a day
2 more recorded rows
humanNCT02607657
Eplerenone 25 mg twice a day
humanNCT03418649
Eplerenone 50 Mg Tab
recorded 2026-09-01 · last checked 2026-09-04
Q5
Eplerenone's half-life is 3 to 6 hours — which schedules were studied?
3 to 6 hours, the half-life Eplerenone's label states. openfda-label · bcd7595f-700f-48ba-bf83-05a995ce0731 · 2026-08-30
bioavailability 69% %.
Show the evidence
half life
3 to 6 hours hours; 12.3 Pharmacokinetics Eplerenone is cleared predominantly by cytochrome P450 (CYP) 3A4 metabolism, with an elimination half-life of 3 to 6 hours.
bioavailability
69% %; The absolute bioavailability of eplerenone is 69% following administration of a 100 mg oral tablet.
metabolism
12.3 Pharmacokinetics Eplerenone is cleared predominantly by cytochrome P450 (CYP) 3A4 metabolism, with an elimination half-life of 3 to 6 hours.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Eplerenone's effect on left ventricular mass?
Left ventricular mass: measured in Eplerenone's trials.
Interpretation left ventricular mass is the recorded endpoint.
Show the evidence
biomarkers
left ventricular mass; 2026-09-01
decrease in supine systolic blood pressure; 2026-09-01
proteinuria; 2026-09-01
blood pressure by home measurements; 2026-09-01
seated trough cuff diastolic blood pressure at week 8; 2026-09-01
basal metabolic rate; 2026-09-01
14 more recorded rows
biomarkers
pulse wave velocity; 2026-09-01
biomarkers
clinically significant effects; 2026-09-01
biomarkers
cmax; 2026-09-01
biomarkers
glycated hemoglobin; 2026-09-01
biomarkers
plasma insulin; 2026-09-01
biomarkers
cortisol; 2026-09-01
biomarkers
adiponectin; 2026-09-01
biomarkers
nt probnp; 2026-09-01
biomarkers
ascites; 2026-09-01
biomarkers
galectin 3; 2026-09-01
biomarkers
muscle sympathetic nerve activity at rest; 2026-09-01
biomarkers
insulin secretion; 2026-09-01
biomarkers
insulin sensitivity; 2026-09-01
biomarkers
sitting systolic and diastolic blood pressure; 2026-09-01
half life
2026-09-04; halfLife; hours; 3 to 6 hours; 2026-08-30
human trials at or under30
36
smallest human trial
0; NCT01275352; PHASE4; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of 24 hour systolic ambulatory blood pressure, adiponectin and adverse events as a measure of safety and tolerability did Eplerenone's trials measure?
24 hour systolic ambulatory blood pressure, adiponectin and adverse events as a measure of safety and tolerability lead 39 outcome terms across Eplerenone's trials. ClinicalTrials.gov · 2026-09-01
blood pressure by home measurements, seated trough cuff diastolic blood pressure at week 8, basal metabolic rate, pulse wave velocity, clinically significant effects and cmax follow.
Show the evidence
left ventricular mass
1
decrease in supine systolic blood pressure
1
proteinuria
1
blood pressure by home measurements
1
seated trough cuff diastolic blood pressure at week 8
1
basal metabolic rate
1
14 more recorded rows
pulse wave velocity
1
clinically significant effects
1
cmax
1
glycated hemoglobin
1
plasma insulin
1
cortisol
1
adiponectin
1
nt probnp
1
ascites
1
galectin 3
1
muscle sympathetic nerve activity at rest
1
insulin secretion
1
insulin sensitivity
1
sitting systolic and diastolic blood pressure
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Eplerenone's 12 ongoing trials reports first?
"Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)"; n 132; "Iohexol clearance"; 2031-08
NCT03984591
"A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure"; n 7200; "Mortality"; 2028-12-31
NCT04840342
"MR Antagonist and LSD1"; n 300; "24-hour systolic ambulatory blood pressure"; 2026-06
NCT05030545
"Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study"; n 40; "Change in myocardial flow reserve (MFR, unitless ratio)"; 2027-02-28
NCT05198791
"Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries."; n 400; "Within patient change in NTproBNP"; 2026-07-31
NCT05593055
"Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension"; n 75; "Change in myocardial flow reserve"; 2027-12-31
6 further recorded trials
NCT06168994
"Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease"; n 100; "Role of eplerenone in reducing recurrence of atrial fibrillation in patient with structural heart disease"; 2027-05-20
NCT06749418
"Vascular Effects of High-Salt After Preeclampsia"; n 40; "Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry"; 2027-11-15
NCT07029503
"Swedish Cardiac And Renal Failure Study-1"; n 40; "The primary endpoint is the proportion of participants who complete the treatment period with and without the need to use a potassium binder"; 2027-10
NCT07345845
"MR and Inflammation After Preeclampsia"; n 40; "Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry"; 2029-02-01
NCT07727252
"Early Aldo Blockade in Subclinical PA"; n 880; "Incidence of New-Onset Hypertension"; 2029-08-01
NCT07795762
"Eplerenone and IOP in Healthy Adults"; n 30; "Change in Mean Intraocular Pressure With Eplerenone Compared With Placebo"; 2027-04-01
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which running trial of Eplerenone could settle lifespan?
NCT03984591 measures Mortality, reading out 2028-12-31.
1 open trial; n 7200; "A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure"
Show the evidence
TrialNCT03984591
"A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure"; n 7200; "Mortality"; 2028-12-31
Q10
Which 31 trials of Eplerenone posted no result?
Posted no result
31 of 31 completed trials
Registrations
NCT00082589, NCT00214825, NCT00147615, NCT00147589, NCT00108251 and NCT00138944, and 25 more
Completion dates
oldest 2006-03; newest 2021-10
Show the evidence
Trial
NCT00082589
2006-03
NCT00214825
2006-03
NCT00147615
2006-06
NCT00147589
2007-01
NCT00108251
2007-10
NCT00138944
2008-07
14 further recorded trials
NCT00505336
2008-12
NCT00430924
2009-08
NCT00703352
2010-12
NCT01473108
2011-05-17
NCT00315016
2011-07
NCT01319344
2013-04
NCT00401856
2013-04-02
NCT01650012
2013-12
NCT01837108
2014-01
NCT01955694
2015-02-20
NCT02345044
2015-10
NCT02118753
2016-01
NCT02462499
2016-09
NCT00223717
2017-01
Q11
At the median, Eplerenone's trials enrolled 42.5 people — anything larger?
Median enrolment
42.5
Largest enrolment
22213
Registered trials counted
102
Q12
What do 1369 spontaneous reports say about Eplerenone — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Eplerenone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 1369 reaction mentions were counted: acute kidney injury 272; hypotension 193; hyperkalaemia 162; cardiac failure 161. open-targets-adr · CHEMBL1095097 · 2026-06-24
Show the evidence
acute kidney injury
272
hypotension
193
hyperkalaemia
162
cardiac failure
161
dyspnoea
158
oedema peripheral
110
4 more recorded rows
condition aggravated
92
drug interaction
88
hyponatraemia
73
blood creatinine increased
60
recorded 2026-06-24 · last checked 2026-09-04
Q13
Eplerenone and CYP3A4, CYP1A2 and CYP2C19: shared by which compounds?
CYP3A4, CYP1A2 and CYP2C19 appear in Eplerenone's recorded interaction sentences, 7 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2pharmacokinetics
Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6.
CYP2C19pharmacokinetics
Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6.
CYP2C9pharmacokinetics
Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6.
CYP2D6pharmacokinetics
Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6.
CYP3A4
pharmacokinetics
Metabolism and Excretion Eplerenone metabolism is primarily mediated via CYP3A4.
pharmacokinetics
Drug-Drug Interactions Eplerenone is metabolized primarily by CYP3A4.
pharmacokinetics
Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6.
recorded 2026-08-30 · last checked 2026-09-04
Q14
Was Eplerenone studied with exercise?
exercise is named in Eplerenone's label sentences: "Although eplerenone was not associated with an improvement in exercise capacity compared to placebo, it was associated with significant reduction in markers of collagen turnover and improvement in diastolic function." openfda-label+europepmc · 2026-08-30
1 recorded statement; exercise
Show the evidence
exercise
Although eplerenone was not associated with an improvement in exercise capacity compared to placebo, it was associated with significant reduction in markers of collagen turnover and improvement in diastolic function.
recorded 2026-08-30 · last checked 2026-09-04
Q15
What is recorded about Eplerenone and NAD+?
"The aldosterone levels showed a time-dependent (6-24 h) and dose-dependent (10(-8) to 10(-6) m) increase in superoxide generation, whose effect was abolished by mineralocorticoid receptor antagonist (eplerenone), Src inhibitor (PP2), and reduced nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase inhibitor (apocynin)." — where Eplerenone and NAD+ appear together. Europe PMC · pathway abstract search · 2016-03-22
"The aldosterone levels showed a time-dependent (6-24 h) and dose-dependent (10(-8) to 10(-6) m) increase in superoxide generation, whose effect was abolished by mineralocorticoid receptor antagonist (eplerenone), Src inhibitor (PP2), and reduced nicotinamide adenine dinucleotide phosphate [NAD(P)H] oxidase inhibitor (apocynin)."
PMID 16505212
"Upregulated expression of the mineralocorticoid receptor aldosterone synthase (CYP11B2); NAD(P)H oxidase p22phox, p47phox, gp91phox, iNOS, and LOX-1; and activated p65 NF-kappaB, protein kinase CbetaII, c-Src, p44/p42 extracellular signal-regulated kinase, and p70S6 kinase phosphorylation were inhibited by eplerenone."
mTORPMID 27006450
"In PASMCs transfected with Raptor-small interfering RNA or treated with spironolactone/eplerenone, aldosterone or pulmonary arterial plasma from patients with PAH failed to increase p70S6K activation or to induce cell survival in vitro Optimal inhibition of pulmonary arteriole Raptor was achieved by treatment with Staramine-monomethoxy polyethylene glycol that was formulated with Raptor-small…"
NAD+PMID 16115035
"Endothelium-dependent and -independent relaxations, as well as endothelial nitric oxide synthase (eNOS) and the subunit p22phox of NAD(P)H oxidase mRNA expressions, were studied in aorta from SHR untreated or treated with eplerenone."
recorded 2016-03-22 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.